Summary
This paper explores antimicrobial blue light therapy (aBL) as a non-antibiotic approach to treating biofilm wound infections, particularly MRSA, which can be 100–1000-fold more resistant to antibiotics than planktonic bacteria. The findings suggest menadione (Vitamin K3) acts as a synergistic photosensitizer and ROS recycler, enhancing aBL's microbicidal effectiveness and offering a potential alternative to conventional antibiotic therapy.
Key Findings
- Bacteria in biofilms may be 100–1000-fold more resistant to antibiotics compared to their clinical laboratory minimal inhibitory concentration (MIC).
- MRSA caused more deaths globally than any other pathogen-antibiotic resistant combination in a recent worldwide statistical review.
- Menadione (Vitamin K3) synergizes with antimicrobial blue light therapy to increase both ROS generation and microbicidal effects in biofilm infections using in vitro and ex vivo porcine skin models.
Categories
The Science of Light: Investigates blue light's antimicrobial phototherapy mechanisms, specifically ROS generation and its application in treating biofilm infections.
Author(s)
A Ferré Ferré
Publication Year
2015
Related Publications
The Science of Light
- Phototransduction by retinal ganglion cells that set the circadian clock
- Color appearance models
- The mammalian circadian timing system: organization and coordination of central and peripheral clocks
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Melanopsin is required for non-image-forming photic responses in blind mice